The braftovi/mektovi (BRAF/MEK) inhibitor-induced pyroptosis can induce changes in the tumor immune microenvironment and improve the therapeutic effect of drug-resistant melanoma, which provides a new direction for scorch-mediated anti-tumor immunity and treatment of drug-resistant tumors. The gene discussed is BRAF; the disease is melanoma.